Pharmafile Logo

sipuleucel-T

Eli Lilly HQ

Pfizer and Lilly restart tanezumab pain trials

FDAlifts clinical block on late-stage studies of the novel painkiller

National Institute for Health and Care Excellence NICE logo

NICE system ‘slowing market access to cancer meds’

Two new reports show that UK access to new treatments and survival rates among lowest in Europe

- PMLiVE

NICE gives nod to blood cancer drug Gazyvaro

Roche’s leukaemia drug to be used in combination with chemotherapy

- PMLiVE

Cancer Drugs Fund cull ‘won’t save NHS money’

New survey also finds that oncologists believe the cuts will ‘worsen patient outcomes’

- PMLiVE

NICE recommends BMS and Pfizer’s Eliquis for blood clots

Will be a treatment option for venous thromboembolism

National Institute for Health and Care Excellence NICE logo

Patients should have a say in their medication, claims NICE

Also states health practitioners should be able to share information

- PMLiVE

Gilead’s Harvoni gains NICE yes – but won’t face funding delay

Unlike the company's Sovaldi, which won’t be paid for until the summer

National Institute for Health and Care Excellence NICE logo

NICE backs biosimilars in rheumatoid arthritis guidance

Seven biologic drugs (DMARDs) and two biosimilars recommended

Gilead Sciences

Gilead’s Sovaldi wins NICE approval but faces access delay

The Institute also recommends Janssen's hepatitis C drug Olysio

- PMLiVE

Future gazing: What does 2015 hold for NICE?

Undermined by the CDF, the Institute is set to face a number of challenges this year

National Institute for Health and Care Excellence NICE logo

Good NICE news for Pfizer, but Dendreon drug rejected

Kidney cancer drug Inlyta backed but prostate cancer treatment Provenge is not

- PMLiVE

England’s medicine prices ‘too high’

New analysis finds NICE is too lenient on pharma’s price tags

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links